--- title: "Nektar Therap | 8-K: FY2025 Revenue Beats Estimate at USD 55.23 M" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/278942142.md" datetime: "2026-03-12T20:49:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278942142.md) - [en](https://longbridge.com/en/news/278942142.md) - [zh-HK](https://longbridge.com/zh-HK/news/278942142.md) --- > 支持的语言: [English](https://longbridge.com/en/news/278942142.md) | [繁體中文](https://longbridge.com/zh-HK/news/278942142.md) # Nektar Therap | 8-K: FY2025 Revenue Beats Estimate at USD 55.23 M Revenue: As of FY2025, the actual value is USD 55.23 M, beating the estimate of USD 43.78 M. EPS: As of FY2025, the actual value is USD -9.73, beating the estimate of USD -9.9265. EBIT: As of FY2025, the actual value is USD -124.36 M. The provided reference is a Form 8-K filing by Nektar Therapeutics (内克塔治疗) stating that the company issued a press release on March 12, 2026, announcing its financial results for the quarter ended December 31, 2025. The actual financial results, operational metrics, and any outlook or guidance are contained within the referenced press release (Exhibit 99.1), which is not provided in this document. Therefore, no specific financial or operational metrics, nor any outlook or guidance, can be extracted from the given text. ### 相关股票 - [Nektar Therap (NKTR.US)](https://longbridge.com/zh-CN/quote/NKTR.US.md) ## 相关资讯与研究 - [Nekkar ASA Completes Share Buy-Backs Worth NOK 44.65 Million](https://longbridge.com/zh-CN/news/273663404.md) - [Nanalysis Sets Date for Q4 and Full-Year 2025 Results Call](https://longbridge.com/zh-CN/news/281538578.md) - [Itaú Unibanco Files Q4 2025 Pillar 3 Risk and Capital Report With Strong Capital Ratios](https://longbridge.com/zh-CN/news/281508938.md) - [SunPower files to delay 10-K, expects significant upside changes in FY 2025 results](https://longbridge.com/zh-CN/news/281182236.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-CN/news/281530653.md)